Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$1.58M$1.58M−5.9% vs Q3 2023 Net Income-$2.22M-$2.22MN/M vs Q3 2023 EPS Diluted-$16.65-$16.65N/M vs Q3 2023 Gross Profit$1,289,361+1.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
Operating Cash Flowderived-$771,246N/M Margins · derivedGross margin81.8%+6.2 pt vs Q3 2023
Operating margin-76.0%+211.1 pt vs Q3 2023
Net margin-140.9%+130.8 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end